Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study

MT Newswires Live10-18

Kezar Life Sciences (KZR) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review.

Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4 or 5 serious adverse events. It is looking to report topline data in the first half of 2025.

The company, meanwhile, said it would discontinue the Palizade phase 2b trial of zetomipzomib in patients with active lupus nephritis and focus on developing the drug for autoimmune hepatitis. The decision followed the IDMC's assessment of four fatal serious adverse events in the Philippines and Argentina, Kezar said.

Shares of the company were down more than 8% in recent trading.

Price: 0.82, Change: -0.08, Percent Change: -8.48

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476822374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-18 02:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476822374","market":"sh","top_or_hot":-1,"title":"Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study","media":"MT Newswires Live","content":"<html><body><p> Kezar Life Sciences (KZR) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review.</p><p>Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4 or 5 serious adverse events. It is looking to report topline data in the first half of 2025.</p><p>The company, meanwhile, said it would discontinue the Palizade phase 2b trial of zetomipzomib in patients with active lupus nephritis and focus on developing the drug for autoimmune hepatitis. The decision followed the IDMC's assessment of four fatal serious adverse events in the Philippines and Argentina, Kezar said.</p><p>Shares of the company were down more than 8% in recent trading.</p><p>Price: 0.82, Change: -0.08, Percent Change: -8.48</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-18 02:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kezar Life Sciences (KZR) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7095","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476822374","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476822374","pubTimestamp":1729190689,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kezar Life Sciences  said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review.Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4 or 5 serious adverse events. It is looking to report topline data in the first half of 2025.The company, meanwhile, said it would discontinue the Palizade phase 2b trial of zetomipzomib in patients with active lupus nephritis and focus on developing the drug for autoimmune hepatitis. The decision followed the IDMC's assessment of four fatal serious adverse events in the Philippines and Argentina, Kezar said.Shares of the company were down more than 8% in recent trading.Price: 0.82, Change: -0.08, Percent Change: -8.48","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7095":"多种金属与采矿","KZR":"Kezar Life Sciences Inc.","BK4139":"生物科技","KZR.AU":"KALAMAZOO RESOURCES LIMITED"},"translate_title":"Kezar Life Sciences获准继续进行自身免疫性肝炎试验；狼疮性肾炎研究结束","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZR.AU":1,"KZR":0.9},"content_text":"Kezar Life Sciences (KZR) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review.Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4 or 5 serious adverse events. It is looking to report topline data in the first half of 2025.The company, meanwhile, said it would discontinue the Palizade phase 2b trial of zetomipzomib in patients with active lupus nephritis and focus on developing the drug for autoimmune hepatitis. The decision followed the IDMC's assessment of four fatal serious adverse events in the Philippines and Argentina, Kezar said.Shares of the company were down more than 8% in recent trading.Price: 0.82, Change: -0.08, Percent Change: -8.48","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476822374"}